Supportive care measures

Phase 3Small molecule

Supportive care measures is one of 264 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

263

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaRecruiting

Esophageal CancerActive, not recruiting

Intestinal CancerActive, not recruiting

Esophageal AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Colorectal CancerRecruiting

Bladder CancerActive, not recruiting

Non Muscle Invasive Bladder CancerRecruiting

Non-Small Cell Lung Cancer (NSCLC)Recruiting

Urothelial CarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaPreclinical

Recruiting

Esophageal CancerPhase 1/Phase 2

Active, not recruiting

Intestinal CancerPhase 1/Phase 2

Active, not recruiting

Esophageal AdenocarcinomaPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Colorectal CancerPreclinical

Recruiting

Bladder CancerPhase 1/Phase 2

Active, not recruiting

Non Muscle Invasive Bladder CancerPreclinical

Recruiting

Non-Small Cell Lung Cancer (NSCLC)Phase 3

Recruiting

Urothelial CarcinomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Supportive care measures

Merck & Co.

Phase 3

7 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Remeron

OOrganon and Co

Preclinical

1 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Sacituzumab Tirumotecan

NCT06049212

Q2 2027

Phase 3Active, not recruiting

Esophageal Adenocarcinoma

NCT06356311

Q1 2028

Phase 1/2Active, not recruiting

Urothelial Carcinoma

NCT06483334

Q1 2029

PreclinicalRecruiting

Non Muscle Invasive Bladder Cancer

NCT06637423

Clinical

Trials by Indication[1]

Sacituzumab Tirumotecan1 trial

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT06049212·30 enrolled

Esophageal Adenocarcinoma1 trial

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06356311·450 enrolled

Urothelial Carcinoma1 trial

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT06483334·38 enrolled

Non Muscle Invasive Bladder Cancer1 trial

A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06637423·32 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06170788·614 enrolled

2 more indications

Colorectal Cancer1 trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06428409·220 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT05319730·230 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Supportive care measures. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Supportive care measures compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Supportive care measures. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Supportive care measures

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q1 2028

Q1 2029

Trials by Indication[1]

Sacituzumab Tirumotecan1 trial

Esophageal Adenocarcinoma1 trial

Urothelial Carcinoma1 trial

Non Muscle Invasive Bladder Cancer1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

Colorectal Cancer1 trial

Esophageal Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News